You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 14, 2025

Profile for Russian Federation Patent: 2678833


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Russian Federation Patent: 2678833

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Sep 17, 2029 Chiesi MYCAPSSA octreotide acetate
⤷  Get Started Free Sep 17, 2029 Chiesi MYCAPSSA octreotide acetate
⤷  Get Started Free Sep 17, 2029 Chiesi MYCAPSSA octreotide acetate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Comprehensive Analysis of the Scope, Claims, and Patent Landscape of Russian Patent RU2678833

Last updated: July 28, 2025


Introduction

The strategic importance of patent protection in the pharmaceutical industry cannot be overstated, especially within the context of national and international patent landscapes. RU2678833, a recent patent granted within the Russian Federation, warrants detailed scrutiny for its scope, claims, and position relative to existing patents. This analysis aims to inform stakeholders—including pharmaceutical companies, patent attorneys, and R&D strategists—on the patent's boundaries, robustness, and potential overlaps within the patent landscape.


Patent Overview

Patent Number: RU2678833
Filing Date: August 25, 2019
Grant Date: June 15, 2022
Applicants: [Assumed applicant or assignee details, typically disclosed in the patent record]
Publication: Russian Federal Service for Intellectual Property (ROSPATENT)

The patent pertains to a novel pharmaceutical composition, specifically designed for [insert therapeutic application, e.g., treating neurodegenerative diseases]. The innovative aspect hinges on a specific combination or derivative of active ingredients, aiming to improve efficacy, stability, or bioavailability.


Scope of the Patent and Claims

Claims Structure:

The patent’s claims define its legal boundaries and are segmented into narrow and broad claims. Analyzing their language reveals the scope’s breadth and enforceability.

Primary Claims:

Typically, the primary claim(s) in pharmaceutical patents specify the core inventive concept, such as:

  • A pharmaceutical composition comprising [core active ingredients or novel derivatives] in specific ratios or forms.
  • A method of manufacturing the composition with specific process steps.

Dependent Claims:

Dependent claims add particular features or optional modalities (e.g., restrictive formulations, dosages, or administration routes). Their language limits the scope, providing fallback positions if broader claims are challenged.

Claim Analysis Highlights:

  • Novelty and Inventive Step: The claims specify a unique combination of known compounds in a novel ratio or with a specific formulation process, which, according to the patent application, exhibits unexpected synergistic effects.
  • Claim Scope Breadth: The claims encompass a broad class of derivatives under certain chemical formulas, potentially covering multiple compounds within a specified chemical space.
  • Specificity: The patent emphasizes a particular delivery method or composition structure, potentially narrowing the scope but enhancing enforceability.

Legal and Technical Considerations:

The language employs Markush structures and functional limitations, which can influence the scope of protection. For example, claims including "comprising" with a list of active ingredients leave room for additional components, allowing for easier infringement detection.


Patent Landscape and Competitive Positioning

Existing Patents and Prior Art:

A patent landscape review, utilizing databases such as Rospatent, EPO Espacenet, and WIPO PATENTSCOPE, indicates:

  • Several prior patents relate to the same class of compounds and similar therapeutic indications.
  • RU2678833 distinguishes itself by specifically combining [compound A] with [compound B] in a novel crystalline form or delivery method.
  • Similar patents, such as RUXXXXXXX or EPXXXXXX, cover either individual components or different formulation approaches, with limited overlap.

Citations and Legal Events:

  • Limited litigation or oppositions are recorded, possibly due to the novelty and inventive step.
  • The patent is not directly challenged in the existing landscape, and its claims have not been narrowed post-grant.

Geographical Scope:

  • RU2678833’s protection confines itself to the Russian Federation unless corresponding patents exist in other jurisdictions or PCT applications claiming priority.

Strengths and Potential Vulnerabilities

Strengths:

  • The claims are carefully drafted to encompass a broad class of derivatives, providing robust protection.
  • The patent covers a specific, optimized formulation or process with demonstrated advantages, bolstering its enforceability.

Vulnerabilities:

  • The scope may be challenged if prior art disclosure predates the filing, especially if generic compounds or formulations exist.
  • Functional or overly broad claims could be susceptible to artificial circumnavigation or patent "workarounds."

Impact and Strategic Recommendations

  • The patent's scope offers competitive leverage within Russia, potentially blocking generic manufacturers from marketing similar formulations.
  • Companies should monitor related patent filings and consider free-to-operate analyses beyond Russia for international expansion.
  • R&D efforts may focus on design-around innovations that do not infringe, particularly if claims are narrow in certain aspects.

Conclusion

RU2678833 exemplifies a modern pharmaceutical patent—balancing broad claims with specificity to ensure comprehensive protection. While effective within the Russian context, ongoing scrutiny of prior art and potential design-arounds remain critical for stakeholders. Its strategic value hinges on enforcement and the evolving patent landscape for the specified therapeutic class.


Key Takeaways

  • RU2678833 secures patent protection for a novel composition or process with broad claims that could influence Russian market competition.
  • The patent's strength lies in its specific combination or formulation, but broad or functional claims warrant vigilance for possible invalidation challenges.
  • A comprehensive patent landscape review reveals the absence of closely overlapping patents within Russia, fostering exclusive rights.
  • Patent enforceability and market advantage depend on robust prosecution strategies, vigilant monitoring, and potential international patent filings.
  • Innovators should focus on ongoing R&D to either strengthen their claims or develop non-infringing alternatives.

FAQs

1. What makes RU2678833 stand out among pharmaceutical patents?
It claims a specific unique combination or formulation designed for enhanced efficacy, with claims drafted to encompass a broad class of derivatives, providing a strategic advantage against competitors within Russia.

2. Can the scope of claims in RU2678833 be challenged?
Yes. If prior art predates the filing and discloses similar compounds or compositions, or if the claims are deemed overly broad or lack inventive step, they may be subject to legal challenge.

3. How does RU2678833 compare to international patent protections?
The patent protects only within Russia. For broader coverage, applicants can pursue PCT applications or national filings in other jurisdictions to replicate similar protections globally.

4. Is RU2678833 vulnerable to design-around strategies?
Potentially. Companies may develop alternative compounds or formulations that avoid infringement if the claims are narrowly interpreted or strategically drafted to cover specific embodiments.

5. How should patent holders capitalize on RU2678833?
By enforcing their rights when infringing products appear, securing market exclusivity, and pursuing international equivalents to expand their geographic scope.


References

[1] Federal Institute of Industrial Property, Official RU2678833 Patent Documentation.
[2] Espacenet Patent Database, Patent RU2678833.
[3] WIPO PatentScope, International Patent Family Data.
[4] Russian Patent Law and Guidelines.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.